KANDEROVA, Veronika, Tamara SVOBODOVA, Simon BORNA, Martina FEJTKOVA, Vendula MARTINU, Jana PADEROVA, Michael SVATON, Jarmila KRALOVA, Eva FRONKOVA, Adam KLOCPERK, Stepanka PRUHOVA, Min Ae LEE-KIRSCH, Ludmila HORNOFOVA, Miroslav KOBLIZEK, Petr NOVAK, Olga ZIMMERMANNOVA, Zuzana PARACKOVA, Anna SEDIVA, Tomas KALINA, Ales JANDA, Jana KAYSEROVA, Marcela DVORAKOVA, Milan MACEK, Petr POHUNEK, Petr SEDLACEK, Ashleigh POH, Matthias ERNST, Tomas BRDICKA, Ondrej HRUSAK a Jan LEBL. Early-onset pulmonary and cutaneous vasculitis driven by constitutively active SRC-family kinase HCK. Journal of allergy and clinical immunology. New York: Mosby-Elsevier, 2022, roč. 149, č. 4, s. 1464-1472, 12 s. ISSN 0091-6749. Dostupné z: https://dx.doi.org/10.1016/j.jaci.2021.07.046.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Early-onset pulmonary and cutaneous vasculitis driven by constitutively active SRC-family kinase HCK
Autoři KANDEROVA, Veronika, Tamara SVOBODOVA, Simon BORNA, Martina FEJTKOVA, Vendula MARTINU, Jana PADEROVA, Michael SVATON, Jarmila KRALOVA, Eva FRONKOVA, Adam KLOCPERK, Stepanka PRUHOVA, Min Ae LEE-KIRSCH, Ludmila HORNOFOVA, Miroslav KOBLIZEK, Petr NOVAK, Olga ZIMMERMANNOVA, Zuzana PARACKOVA, Anna SEDIVA, Tomas KALINA, Ales JANDA, Jana KAYSEROVA, Marcela DVORAKOVA, Milan MACEK, Petr POHUNEK, Petr SEDLACEK, Ashleigh POH, Matthias ERNST, Tomas BRDICKA, Ondrej HRUSAK a Jan LEBL.
Vydání Journal of allergy and clinical immunology, New York, Mosby-Elsevier, 2022, 0091-6749.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30102 Immunology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 14.200
Kód RIV RIV/00216224:14740/22:00128769
Organizační jednotka Středoevropský technologický institut
Doi http://dx.doi.org/10.1016/j.jaci.2021.07.046
UT WoS 000820784100013
Klíčová slova anglicky SRC-family kinase; hematopoietic cell kinase; inborn error of immunity; pulmonary hemorrhage; cutaneous vasculitis; autoinflammation; inflammatory cytokines; reactive oxygen species; ruxolitinib
Štítky ne MU, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Pavla Foltynová, Ph.D., učo 106624. Změněno: 5. 4. 2023 10:44.
Anotace
Background: Inborn errors of immunity are genetic disorders characterized by various degrees of immune dysregulation that can manifest as immune deficiency, autoimmunity, or autoinflammation. The routine use of next-generation sequencing in the clinic has facilitated the identification of an ever-increasing number of inborn errors of immunity, revealing the roles of immunologically important genes in human pathologies. However, despite this progress, treatment is still extremely challenging. Objective: We sought to report a new monogenic autoinflammatory disorder caused by a de novo activating mutation, p.Tyr515*, in hematopoietic cell kinase (HCK). The disease is characterized by cutaneous vasculitis and chronic pulmonary inflammation that progresses to fibrosis. Methods: Whole-exome sequencing, Sanger sequencing, mass spectrometry, and western blotting were performed to identify and characterize the pathogenic HCK mutation. Dysregulation of mutant HCK was confirmed ex vivo in primary cells and in vitro in transduced cell lines. Results: Mutant HCK lacking the C-terminal inhibitory tyrosine Tyr522 exhibited increased kinase activity and enhanced myeloid cell priming, migration and effector functions, such as production of the inflammatory cytokines IL-1 beta, IL-6, IL-8, and TNF-alpha, and production of reactive oxygen species. These aberrant functions were reflected by inflammatory leukocyte infiltration of the lungs and skin. Moreover, an overview of the clinical course of the disease, including therapies, provides evidence for the therapeutic efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in inflammatory lung disease. Conclusions: We propose HCK-driven pulmonary and cutaneous vasculitis as a novel autoinflammatory disorder of inborn errors of immunity.
Návaznosti
90127, velká výzkumná infrastrukturaNázev: CIISB II
VytisknoutZobrazeno: 20. 8. 2024 21:17